Acta Scientific Microbiology (ISSN: 2581-3226)

Research Article Volume 5 Issue 4

Evaluation and Validation of the AusDiagnostics MT-Prep XL and AusDiagnostics Ultraplex-3 [SARS-CoV-2, Influenza and RSV 8-well Assay]

Ngoc Yen Kim Tran1*, Thuy Phan1, Genevieve McKew1,2 and Steven Siarakas1

1Department of Microbiology and Infectious Disease, Concord Repatriation General Hospital, NSW Health Pathology, Concord, NSW, Australia

2Faculty of Medicine and Health, The University of Sydney, Concord, NSW, Australia

*Corresponding Author: Ngoc Yen Kim Tran, Department of Microbiology and Infectious Disease, Concord Repatriation General Hospital, NSW Health Pathology, Concord, NSW, Australia.

Received: February 17, 2022; Published: March 29, 2022

Abstract

A validation study was conducted on the AusDiagnostics MT-Prep XL and AusDiagnostics SARS-CoV-2, Influenza and RSV 8-well assay performed on the AusDiagnostics Ultraplex 3 system. The Cycle threshold (Ct) of clinical patient samples spiked with a positive control, was compared to the reference laboratory standard, AusDiagnostics MT-Prep and Highplex System. The analytical performance was evaluated to establish the limit of detection (LOD), precision and agreement.

There is an average difference in Ct of -0.883 and 0.078 between the nucleic extractors and MT-PCR systems, respectively. There was strong correlation (R-value ranging from 0.78 – 0.91 for all gene targets) between the AusDiagnostics Ultraplex-3 and Highplex. Bland Altman analysis demonstrated the overall differences between the assays are within the limits of agreement (LoA). The AusDiagnostics MT-Prep XL has a processing time of 1.04 minute/sample and AusDiagnostics Ultraplex 3, 1.93 minute/sample, demonstrating a higher efficiency rate compared to the reference standard.

RSV and SARS-CoV-2 detection in clinical samples were compared to the AusDiagnostics Highplex system as a reference standard. The assay demonstrated 99.10% overall agreement, with a PPA 100% and NPA of 99%. Kappa statistics of 0.95 (p < 0.05) suggests excellent agreement level between the two platforms. Moreover, precision study was conducted to observe the intra-run and inter-run assay variability. The calculated average Ct observed in all targets is 1.063% and 1.682%, respectively. The CV% is <2% suggesting high precision, low variability, and dispersion in data points.

The commercialized AusDiagnostics MT-Prep XL and Ultraplex 3 is a viable platform, fit for purpose in detecting the SARS-CoV-2, Influenza A, Influenza B and RSV respiratory viruses.

It’s high efficiency rate and 96-sample capacity enhances laboratory throughput and enables faster time to result in comparison to the current reference standard.

Keywords: COVID-19; Influenza; Respiratory Syncytial Virus; Laboratory Diagnosis; MT-PCR

References

  1. Hu B., et al. “Characteristics of SARS-CoV-2 and COVID-19”. Nature Reviews Microbiology 19 (2021): 141-154.
  2. Adil MT., et al. “SARS-CoV-2 and the pandemic of COVID-19”. Postgraduate Medical Journal 97 (2021): 110-116.
  3. “AusDiagnostics MT-Prep XL”. MT-PrepTM XL (2021).
  4. “AusDiagnostics Ultraplex 3”. Ultraplex 3 (2021).
  5. Abdelrahman Z., et al. “Comparative review of SARS-CoV-2, SARS-CoV, MERS-CoV2, and Influenza A Respiratory Viruses”. Frontiers in Immunology 11 (2020): 1-14.
  6. Jansen AGSC., et al. “Influenza-and respiratory syncytial virus-associated mortality and hospitalisations”. European Respiratory Journal 30 (2007): 1158-1166.
  7. Moghadami M. “A narrative review of Influenza: A seasonal and pandemic disease”. IJMS 42 (2017): 1-13.
  8. Borchers AT., et al. “Respiratory syncytial virus – A comprehensive review”. Clinical Reviews in Allergy and Immunology 45 (2013): 331-379.
  9. Solomon DA., et al. “Influenza in the COVID-19 Era”. JAMA Insights Clinical 324 (2020): 1342-1343.
  10. Mancini F., et al. “Multiplex real-time reverse transcription polymerase chain reaction assays for diagnostic testing of severe acute respiratory syndrome Coronavirus 2 and seasonal influenza viruses: A challenge of the Phase 3 pandemic setting”. The Journal of Infectious Diseases 223 (2021): 765-774.
  11. Australian Government Department of Health. Australian influenza surveillance report – 2020 national influenza season summary (2020).

Citation

Citation: Ngoc Yen Kim Tran., et al. “Evaluation and Validation of the AusDiagnostics MT-Prep XL and AusDiagnostics Ultraplex-3 [SARS-CoV-2, Influenza and RSV 8-well Assay]". Acta Scientific Microbiology 5.4 (2022): 156-165.

Copyright

Copyright: © 2022 Ngoc Yen Kim Tran., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.




Metrics

Acceptance rate30%
Acceptance to publication20-30 days

Indexed In






News and Events


  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is July 10, 2022.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of “Best Article of the Issue”.
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.
  • Contact US